CA2590224C - Method for reduction, stabilization and prevention of rupture of lipid rich plaque - Google Patents

Method for reduction, stabilization and prevention of rupture of lipid rich plaque Download PDF

Info

Publication number
CA2590224C
CA2590224C CA2590224A CA2590224A CA2590224C CA 2590224 C CA2590224 C CA 2590224C CA 2590224 A CA2590224 A CA 2590224A CA 2590224 A CA2590224 A CA 2590224A CA 2590224 C CA2590224 C CA 2590224C
Authority
CA
Canada
Prior art keywords
pharmaceutically acceptable
pitavastatin
rupture
hydrate
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2590224A
Other languages
English (en)
French (fr)
Other versions
CA2590224A1 (en
Inventor
Hideyuki Kobayashi
Yasunobu Yoshinaka
Kimiyuki Shibuya
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kowa Co Ltd
Original Assignee
Kowa Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co Ltd filed Critical Kowa Co Ltd
Publication of CA2590224A1 publication Critical patent/CA2590224A1/en
Application granted granted Critical
Publication of CA2590224C publication Critical patent/CA2590224C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2590224A 2004-12-10 2005-12-09 Method for reduction, stabilization and prevention of rupture of lipid rich plaque Expired - Fee Related CA2590224C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63453204P 2004-12-10 2004-12-10
US60/634,532 2004-12-10
PCT/JP2005/023088 WO2006064889A1 (en) 2004-12-10 2005-12-09 Method for reduction, stabilization and prevention of rupture of lipid rich plaque

Publications (2)

Publication Number Publication Date
CA2590224A1 CA2590224A1 (en) 2006-06-22
CA2590224C true CA2590224C (en) 2011-12-20

Family

ID=36587943

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2590224A Expired - Fee Related CA2590224C (en) 2004-12-10 2005-12-09 Method for reduction, stabilization and prevention of rupture of lipid rich plaque

Country Status (11)

Country Link
US (2) US20090275595A1 (https=)
EP (1) EP1827440A4 (https=)
JP (1) JP2008522955A (https=)
KR (1) KR100895031B1 (https=)
CN (1) CN101068548B (https=)
AU (1) AU2005314810B2 (https=)
CA (1) CA2590224C (https=)
NZ (1) NZ554924A (https=)
RU (1) RU2351337C1 (https=)
TW (1) TW200619204A (https=)
WO (1) WO2006064889A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060111898A (ko) * 2003-08-29 2006-10-30 교와 가부시키가이샤 지질-풍부-플라크의 안정화 방법 및 파열 예방방법
US8048083B2 (en) * 2004-11-05 2011-11-01 Dfine, Inc. Bone treatment systems and methods
WO2011081118A1 (ja) * 2009-12-29 2011-07-07 興和株式会社 経口投与用医薬組成物
JPWO2011081117A1 (ja) * 2009-12-29 2013-05-09 興和株式会社 経口投与用固形医薬組成物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (da) * 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
JP2569746B2 (ja) * 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
US5177080A (en) * 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
US5491172A (en) * 1993-05-14 1996-02-13 Warner-Lambert Company N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
AU720853B2 (en) * 1995-11-02 2000-06-15 Warner-Lambert Company Method and pharmaceutical composition for regulating lipid concentration
HUP0002294A3 (en) * 1997-05-26 2001-10-29 Kowa Co Cyclic diamine compounds and medicines containing the same
US6969711B2 (en) * 1997-05-26 2005-11-29 Kowa Company, Ltd. Cyclic diamine compounds and medicine containing the same
RU2235483C2 (ru) * 1998-11-25 2004-09-10 Нутри Фарма Аса Композиция, фармацевтический препарат и способ для профилактики и/или лечения и/или ослабления сердечно-сосудистых заболеваний
WO2001022962A1 (en) * 1999-09-30 2001-04-05 Merck & Co., Inc. Anti-hypercholesterolemic drug combination
AU2001269516B2 (en) * 2000-07-13 2006-09-14 Takeda Pharmaceutical Company Limited Lipid-rich plaque regressing agents
WO2002020009A1 (en) * 2000-09-01 2002-03-14 Sankyo Company, Limited Medicinal compositions
US20060165605A1 (en) * 2001-12-28 2006-07-27 Ye-Mon Chen Process to regenerate fcc spent catalyst
MY140618A (en) * 2003-02-28 2009-12-31 Kowa Co Method for preparing acid addition salts of polyacidic basic compounds
US20060046996A1 (en) * 2004-08-31 2006-03-02 Kowa Co., Ltd. Method for treating hyperlipidemia

Also Published As

Publication number Publication date
KR20070085508A (ko) 2007-08-27
EP1827440A1 (en) 2007-09-05
CA2590224A1 (en) 2006-06-22
RU2351337C1 (ru) 2009-04-10
WO2006064889A1 (en) 2006-06-22
AU2005314810B2 (en) 2010-08-26
NZ554924A (en) 2010-09-30
RU2007125976A (ru) 2009-01-20
KR100895031B1 (ko) 2009-04-24
US20090275595A1 (en) 2009-11-05
CN101068548B (zh) 2010-12-08
JP2008522955A (ja) 2008-07-03
EP1827440A4 (en) 2010-12-08
US20110207742A1 (en) 2011-08-25
AU2005314810A1 (en) 2006-06-22
HK1111356A1 (en) 2008-08-08
CN101068548A (zh) 2007-11-07
TW200619204A (en) 2006-06-16

Similar Documents

Publication Publication Date Title
US5674893A (en) Method for preventing reducing or risk of onset of cerebrovascular events employing an HMG CoA reductase inhibitor
US20070105894A1 (en) Combination of at least two compounds selected from an AT1-receptorantagonist or an ACE inhibitor or a HMG-Co-A reductase inhibitor
CZ286832B6 (en) Compound pharmaceutical preparation for prevention and treatment of arteriosclerosis or xanthoma
BR122018015003B1 (pt) kit compreendendo composições farmacêuticas de inibidor da nep e de valsartan ou seus sais
KR20050012771A (ko) 치환된 시아노피롤리딘의 용도 및 이들을 함유하는고지혈증 및 관련 질환의 치료를 위한 조합 제제
EP2787993B1 (en) TREATMENT OF ARTERIAL WALL BY COMBINATION OF RAAS INHIBITOR AND HMG-CoA REDUCTASE INHIBITOR
US20110207742A1 (en) Method for reduction, stabilization and prevention of rupture of lipid rich plaque
US20150272944A1 (en) Novel triglyceride reducing agent
CN100438872C (zh) 2-[4-[2-(苯并咪唑-2-基-硫代)乙基]哌嗪-1-基]-n-[2,4-二(甲基硫代)-6-甲基-3-吡啶基]乙酰胺的制药用途
CN1330309C (zh) 用于预防或治疗由eNOS表达而引起的疾病的药物
CA2548790A1 (en) Medicinal compositions and combinations
WO2002030425A1 (en) Preventives and remedies for complications of diabetes
JP2007513991A (ja) メタボリック症候群の処置のためのスタチンの使用
HK1111356B (en) Method for reduction, stabilization and prevention of rupture of lipid rich plaque
WO2004091660A1 (ja) Lklf/klf2遺伝子発現促進剤
WO2006011495A1 (ja) 高コレステロール血症及び／又は高トリグリセリド血症治療剤
CA2494801A1 (en) Medicinal composition containing hmg-coa reductase inhibitor
HK1111632B (en) Novel triglyceride reducing agent

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20131210